Follow-up after curative resection for gastric cancer: Is it time to tailor it?

作     者：Paolo Aurello Niccolò Petrucciani Laura Antolino Diego Giulitti Francesco D'Angelo Giovanni Ramacciato 

作者机构：Division of General Surgery Department of Medical and Surgical Sciences and Translational Medicine UOC Chirurgia 3 Sapienza University St.Andrea Hospital Division of Digestive Surgery and Liver TransplantationNice University Hospital 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2017年第23卷第19期

页      面：3379-3387页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：胃的癌症 后续 外科 胃的癌 化疗 监视 复发 标记 成像 

摘      要：There is still no consensus on the follow-up frequency and regimen after curative resection for gastric ***,controversy exists regarding the utility of follow-up in improving survival,and the recommendations of experts and societies vary *** main reason to establish surveillance programs is to diagnose tumor recurrence or metachronous cancers early and to thereby provide prompt treatment and prolong *** the setting of gastric malignancies,other reasons have been put forth:(1)the detection of adverse effects of a previous surgery,such as malnutrition or digestive sequelae;(2)the collection of data;and(3)the identification of psychological and/or social problems and provision of appropriate support to the *** randomized controlled trials on the role of follow-up after curative resection of gastric carcinoma have been ***,the primary retrospective series and systematic reviews on this subject are analyzed and ***,the guidelines from international and national scientific societies are *** is recommended by the majority of institutions;however,there is no real evidence that follow-up can improve long-term survival *** studies have demonstrated that it is possible to stratify patients submitted to curative gastrectomy into different classes according to the risk of ***,promising studies have identified several molecular markers that are related to the risk of relapse and to *** on these premises,a promising strategy will be to tailor follow-up in relation to the patient and tumor characteristics,molecular marker status,and individual risk of recurrence.